Literature DB >> 9815623

Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus.

M Torzewski1, M Sarbia, P Verreet, P Dutkowski, H Heep, R Willers, H E Gabbert.   

Abstract

In the present study, urokinase-type plasminogen activator (uPA) expression in 150 potentially curatively resected SCCs of the esophagus was analyzed immunohistochemically by means of a murine monoclonal antibody (American Diagnostica, Greenwich, CT) and correlated with survival. Altogether, 122 of the 150 tumors (81.3%) expressed different levels of uPA. Among the 122 uPA-positive tumors, 104 (85.2%) showed a weak staining intensity, and 18 (14.8%) showed a strong staining intensity. Among the uPA-positive tumors, 29 (23. 8%) tumors showed a uPA immunoreactivity in 6-25% of all tumor cells, 30 (24.6%) showed a uPA immunoreactivity in 26-50% of all tumor cells, 41 (33.6%) showed a uPA immunoreactivity in 51-75% of all tumor cells, and 22 (18.0%) showed a uPA immunoreactivity in 76-100% of all tumor cells. No significant correlation could be shown between the different patterns of uPA expression and various clinicopathological parameters, such as pT category, pN category, tumor size, histological grade, blood vessel invasion, lymphatic vessel invasion, and inflammatory response. Concerning the overall postoperative survival, no significant differences between uPA-positive and uPA-negative tumors could be verified. This also held true when different cut points in the percentage of uPA-positive tumor cells were used. In contrast, the intensity of uPA staining provided significant prognostic information in that patients with strongly uPA-positive tumors had a poorer outcome than patients with weakly uPA-positive or uPA-negative tumors. Moreover, as shown by stepwise multivariate Cox regression analysis, the intensity of uPA expression was an independent prognostic factor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815623

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

1.  Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.

Authors:  H Shiomi; Y Eguchi; T Tani; M Kodama; T Hattori
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma.

Authors:  Sang Yun Ha; Ki Yeon Kim; Nam Kyung Lee; Moon Gyo Kim; Seok-Hyung Kim
Journal:  Virchows Arch       Date:  2013-11-19       Impact factor: 4.064

3.  High tPA-expression in primary melanoma of the limb correlates with good prognosis.

Authors:  C M Ferrier; S Suciu; W L van Geloof; H Straatman; A M Eggermont; H S Koops; B B Kroon; F J Lejeune; U R Kleeberg; G N van Muijen; D J Ruiter
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

4.  Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance.

Authors:  Yun Che; Jingnan Wang; Yuan Li; Zhiliang Lu; Jianbing Huang; Shouguo Sun; Shuangshuang Mao; Yuanyuan Lei; Ruochuan Zang; Nan Sun; Jie He
Journal:  Cell Death Dis       Date:  2018-07-09       Impact factor: 8.469

5.  Circulating uPA as a potential prognostic biomarker for resectable esophageal squamous cell carcinoma.

Authors:  Xiao He; Xiaoling Xu; Guanxia Zhu; Hong Ye
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.